H. Lundbeck (HLUN-B.CO) Stock Analysis & AI Equity Report
H. Lundbeck (HLUN-B.CO) overview
H. Lundbeck (HLUN-B.CO) stock analysis and AI equity research. For the latest completed financial year, 2024, H. Lundbeck reported revenue of DKK 22,004m and operating profit of DKK 3,270m; the year-end share price was 41.32 DKK and market capitalisation was DKK 40,966m. H. Lundbeck is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get H. Lundbeck's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About H. Lundbeck
H. Lundbeck A/S is a biopharmaceutical company focused on brain health. It researches, develops, manufactures and commercializes medicines for neurological and psychiatric disorders, with strengths in psychiatry and neurology and an expanding portfolio in neuro-specialty and neuro-rare diseases. The company also works with external partners to advance research and develop new treatments.
Generate the H. Lundbeck report
H. Lundbeck is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for H. Lundbeck and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.